Pursuing global expansion in the beauty and aesthetics market with cosmeceuticals and next-generation fillers
[by Ji, Yong Jun] DongKoo Bio&Pharma announced on April 25 that it signed an exclusive supply agreement on April 18 with the Taiwanese conglomerate Chang Tai Energy (hereinafter referred to as Chang Tai) for the cosmeceutical skincare brand Cell Bloom, with the contract valued at around KRW 10 billion (approximately USD 6.9 million).
Chang 바카라사이트 온카판, a local partner, is a leading 바카라사이트 온카판wanese company that has established its growth foundation in the eco-friendly energy and resource recycling industries. In recent years, it has diversified its portfolio into sectors including renewable energy, biotechnology, healthcare, and cosmetics. The company is also accelerating its global expansion efforts, notably through the establishment of a U.S. subsidiary.
The recent entry of Cell Bloom into the Taiwanese market is garnering attention as a case of strategic synergy, combining Chang Tai’s strong local distribution network with 바카라사이트 온카판 Bio&Pharma’s product capabilities and brand value. Cell Bloom was recently granted official product approval by the Taiwanese Ministry of Health and Welfare (MHW), recognizing the product’s quality, safety, and innovation. Backed by a global response system grounded in a quality management framework that complies with international and local regulatory standards, 바카라사이트 온카판 Bio&Pharma plans to further accelerate its overseas expansion, with Taiwan serving as a key stepping stone.
Following the official approval of human-derived exosomes as cosmetic raw materials by the Taiwanese Ministry of Health and Welfare in March 2024, 바카라사이트 온카판 Bio&Pharma has responded quickly to emerging market trends by launching new human- and plant-derived stem cell exosome ampoules through its Taiwan-exclusive export line.
바카라사이트 온카판 Bio&Pharma, which recently became the largest shareholder of AreumMedics through the acquisition of newly issued shares, is actively pursuing global market expansion with its next-generation filler products. The company also plans to further strengthen its global presence in the cosmetics and skin booster sectors through continuous R&D investment, global collaboration, and actively responding to market diversification.
“This exclusive contract in Taiwan represents a strategic milestone in Cell Bloom’s global business expansion, going beyond mere distribution collaboration,” stated Cho Yong-joon, CEO of 바카라사이트 온카판 Bio&Pharma. “We will actively implement a global market strategy focused on Cell Bloom and high-functional skin booster products,” he added.